All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes.
Michelle R LentPeter N BenottiTooraj MirshahiGlenn S GerhardWilliam E StrodelAnthony T PetrickJon D GabrielsenDavid D RolstonChristopher D StillAnnemarie G HirschFahad ZubairAdam CookDavid J CareyG Craig WoodPublished in: Diabetes care (2017)
All-cause mortality benefits of RYGB are driven predominantly by patients with diabetes at the time of surgery. RYGB patients with diabetes were less likely to die of cardiovascular diseases, diabetes, and respiratory conditions than their counterparts without RYGB.
Keyphrases
- roux en y gastric bypass
- cardiovascular disease
- weight loss
- gastric bypass
- type diabetes
- obese patients
- glycemic control
- minimally invasive
- bariatric surgery
- coronary artery bypass
- cardiovascular risk factors
- cardiovascular events
- metabolic syndrome
- insulin resistance
- african american
- respiratory tract
- atrial fibrillation